New cancer clinical trial: NIMBUS: A Phase II Study of Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer

Published on: December 28, 2018 at 12:00PM
Condition:   Breast Cancer
Interventions:   Drug: Nivolumab;   Drug: Ipilimumab
Sponsors:   Dana-Farber Cancer Institute;   Bristol-Myers Squibb
Not yet recruiting
http://bit.ly/2AjKoR2